Regulatory orchestration of FK506 biosynthesis in Streptomyces tsukubaensis NRRL 18488 revealed through systematic analysis [PDF]
iScienceSummary: Streptomyces tsukubaensis NRRL 18488, the primary producer of the immunosuppressant FK506, was analyzed to elucidate regulatory features of secondary metabolism.
Namil Lee +13 more
doaj +2 more sources
Tacrolimus (FK506) promotes placentation and maternal-fetal tolerance through modulating FASN-CEACAM1 pathway [PDF]
Frontiers in ImmunologyThe establishment of placentation and maternal-fetal tolerance are important determinants of a successful pregnancy. Tacrolimus, also known as FK506, is a calcineurin inhibitor that has often been used for pregnant women after solid organ transplantation.
Xinhang Meng +6 more
doaj +2 more sources
Healing of sub-critical femoral osteotomies in mice is unaffected by tacrolimus and deletion of recombination activating gene 1 [PDF]
European Cells & Materials, 2021 Clinical management of delayed healing or non-union of long bone fractures and segmental defects poses a substantial orthopaedic challenge. There are suggestions in the literature that bone healing may be enhanced by inhibiting the activities of T and B ...
T-Y Liu +9 more
doaj +1 more source
Optimization of the precursor supply for an enhanced FK506 production in Streptomyces tsukubaensis
Frontiers in Bioengineering and Biotechnology, 2022 Tacrolimus (FK506) is a macrolide widely used as immunosuppressant to prevent transplant rejection. Synthetic production of FK506 is not efficient and costly, whereas the biosynthesis of FK506 is complex and the level produced by the wild type strain ...
Susann Schulz +12 more
doaj +1 more source
Targeted Metabolomics Analysis Suggests That Tacrolimus Alters Protection against Oxidative Stress
Antioxidants, 2023 Tacrolimus (FK506) is an immunosuppressant that is experiencing a continuous rise in usage worldwide. The related side effects are known to be globally dose-dependent.
Marie Joncquel +14 more
doaj +1 more source
PLoS ONE, 2023 The objective of this study was to determine if locally delivered FK506 could prevent allogeneic nerve graft rejection long enough to allow axon regeneration to pass through the nerve graft.
Brett Davis +8 more
doaj +1 more source
Materials & Design, 2023 FK506 has been widely used to prevent acute rejection in heart transplantation (HT). However, its strong hydrophobicity, poor bioavailability, high pharmacokinetic variability, and narrow therapeutic window are obstacles to its application in HT.
Cheng Deng +8 more
doaj +1 more source
Targeted Therapy for Acute Autoimmune Myocarditis with Nano-Sized Liposomal FK506 in Rats. [PDF]
PLoS ONE, 2016 Immunosuppressive agents are used for the treatment of immune-mediated myocarditis; however, the need to develop a more effective therapeutic approach remains. Nano-sized liposomes may accumulate in and selectively deliver drugs to an inflammatory lesion
Keiji Okuda +19 more
doaj +1 more source
Microbial Cell Factories, 2021 Background FK506, a macrolide mainly with immunosuppressive activity, can be produced by various Streptomyces strains. However, one of the major challenges in the fermentation of FK506 is its insufficient production, resulting in high fermentation costs ...
Qing-Bin Wu +3 more
doaj +1 more source
Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity. [PDF]
, 2016 BackgroundHIV-associated neurocognitive disorders (HAND) continue to be a common morbidity associated with chronic HIV infection. It has been shown that HIV proteins (e.g., gp120) released from infected microglial/macrophage cells can cause neuronal ...
Achim, Cristian +9 more
core +1 more source